Recent Updates
Recently added Catalysts
ANAB

ANAPTYSBIO PRESENTATION Exhibit

Wednesday, January 15, 2020 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ANAPTYSBIO PRESENTATION Exhibit

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+116%
120-day peak, hindsight
Typical move
2.2%
average across 4 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
Etokimab
Phase 2 · Atopic Dermatitis

Full Press Release Details

ANAPTYSBIO PRESENTATION Exhibit.
ShareAdd on Google
Tags: ANAB Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 15, 2020

Biotech snapshot

Cash runway
$286M liquidity · $9M/mo burn
~30 mo
Minimal dilution risk
Lead asset
EtokimabPhase 2
Atopic Dermatitis →

Catalyst track record

+116%
best trade around ANAB's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ANAB.

See every catalyst's timing & PoA →